PARSIPPANY, NJ, Oct 17 (MARKET WIRE) –
DSP Clinical Research announced today that Inc. Magazine named the boutique clinical research organization 220th on its 2008 Inc. 500 list. It is the first time that DSP has been named an Inc. 500 company. Inc. Magazine reported DSP’s three-year revenue growth at 1,143.7% to $6.9 million.
DSP Clinical Research was formed in 1999. The privately held company focuses on providing turnkey clinical research services to small to midsize pharmaceutical and biotechnology companies that have limited internal infrastructure to initiate, manage, and monitor Phase I-IV clinical development programs.
Darlene Panzitta, founder and President of DSP, said, “We have seen significant growth in our business as more and more small companies choose to outsource their clinical development programs to experienced CROs rather than building costly internal organizations. Our clients often are looking for the personalized services we provide that can be hard to get from a large CRO.”
DSP offers a broad range of services that include:
- Study start-up
- Ongoing study management
- Multi-vendor management (central lab, drug supply, IRB, etc.)
- Site monitoring (site selection, initiation, interim, closeout)
- Study rescue/cleanup
- Site and monitor training/auditing
- Data management
- Statistics and medical writing
- FDA submissions
DSP Clinical Research provides complete trial management and monitoring services on a contract basis for local and/or multinational Phase I to IV clinical studies. Close relationships with partner companies allow us to provide our clients with a full suite of study services such as data management, statistics, medical writing, and NDA/PMA submissions.
Copyright 2008, Market Wire, All rights reserved.